Source: New England Journal of MedicineNew England Journal of Medicine, Massachusetts Medical Society, 2017, 376 (22), pp.2134-2146. ⟨10.1056/NEJMoa1613512⟩

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

Authors : Foster, GR; Afdhal, N; Roberts, SK

Subjects: Adult; Aged, 80 and over; Liver Cirrhosis

Source: New England Journal of Medicine. 373:2608-2617

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

Authors : Michael W. Fried; Michael P. Curry; John G. McHutchison

Subjects: Adult; Aged, 80 and over; Liver Cirrhosis

Source: New England Journal of Medicine. 373:2618-2628

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

Authors : Hézode, C; Feld, JJ; Jacobson, IM

Subjects: Adult; Liver Cirrhosis; Male

Source: New England Journal of Medicine. 373:2599-2607

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

Authors : Bruce Rashbaum; Sarah Henn; Eric Hughes

Subjects: Adult; Male; Pyrrolidines

Source: New England Journal of Medicine. 373:714-725

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

Authors : Kristen M. Marks; John G. McHutchison; Paul E. Sax

Subjects: Male; Fluorenes; Genotype

Source: New England Journal of Medicine. 373:705-713

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Telaprevir for Retreatment of HCV Infection

Authors : Zeuzem, S.; Andreone, P.; van der Pol, S.

Subjects: Male; 0301 basic medicine; Antiviral Agents -- adverse effects -- therapeutic use

Source: The New England Journal of Medicine, 364, 25, pp. 2417-28NEW ENGLAND JOURNAL OF MEDICINE

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients

Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

Telaprevir for Retreatment of HCV Infection

اتصل بنا

اتبع